Verastem, Inc. Common Stock VSTM
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:58:57.005Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:06.525921307Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T00:49:00.486188+00:00
Verastem, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 8.06 | 134.2% | 14.9% | |||
| 30Δ | 8.31 | 131.4% | 13.1% | |||
| 35Δ | 8.56 | 128.5% | 11.3% | |||
| 40Δ | 9.73 | 118.1% | 11.9% | 8.81 | 125.7% | 9.5% |
| 45Δ | 9.50 | 117.1% | 10.3% | 9.03 | 122.0% | 7.9% |
| 50Δ | 9.27 | 116.1% | 8.7% | 9.19 | 115.1% | 6.9% |
| 55Δ | 9.05 | 115.0% | 7.0% | 9.35 | 108.2% | 5.8% |
| 60Δ | 9.50 | 101.3% | 4.8% | |||
| 65Δ | 9.66 | 94.4% | 3.8% | |||
| 70Δ | 7.92 | 333.6% | 13.6% | |||
| 75Δ | 7.28 | 359.1% | 11.5% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.06
- IV
- 134.2%
- B/E move
- 14.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.31
- IV
- 131.4%
- B/E move
- 13.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.56
- IV
- 128.5%
- B/E move
- 11.3%
40Δ
- Pseudo strike
- 9.73
- IV
- 118.1%
- B/E move
- 11.9%
- Pseudo strike
- 8.81
- IV
- 125.7%
- B/E move
- 9.5%
45Δ
- Pseudo strike
- 9.50
- IV
- 117.1%
- B/E move
- 10.3%
- Pseudo strike
- 9.03
- IV
- 122.0%
- B/E move
- 7.9%
50Δ
- Pseudo strike
- 9.27
- IV
- 116.1%
- B/E move
- 8.7%
- Pseudo strike
- 9.19
- IV
- 115.1%
- B/E move
- 6.9%
55Δ
- Pseudo strike
- 9.05
- IV
- 115.0%
- B/E move
- 7.0%
- Pseudo strike
- 9.35
- IV
- 108.2%
- B/E move
- 5.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.50
- IV
- 101.3%
- B/E move
- 4.8%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.66
- IV
- 94.4%
- B/E move
- 3.8%
70Δ
- Pseudo strike
- 7.92
- IV
- 333.6%
- B/E move
- 13.6%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 7.28
- IV
- 359.1%
- B/E move
- 11.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 133.09% | |
| 116.87% | |
| 151.33% | |
| 137.61% | |
| 156.83% | |
| 142.94% | |
| 144.98% | |
| 144.44% | |
| 150.03% | |
| 125.86% |
Biotechnology
VYGR
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered…
More →WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in…
More →WVE
Description unavailable
More →XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in…
More →XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company…
More →XFOR
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back…
More →